《大行報告》大摩料受中美貿戰升級影響較小的中資股名單(表)
摩根士丹利發表報告,挑選出料受中美貿戰升級影響下業務表現仍具彈性的中資股名單: 股份│目標價
嘉里建設(00683.HK)│41港元
九龍倉(00004.HK)│28港元
國電南瑞(600406.SH)│26.7元人民幣
康哲藥業(00867.HK)│10港元
中國財險(02328.HK)│12港元
昆侖能源(00135.HK)│11.5港元
新奧能源(02688.HK)│97港元
華潤燃氣(01193.HK)│46港元
華能電力(00902.HK)│5.9港元
華潤電力(00836.HK)│15港元
國藥控股(01099.HK)│41港元
冀東水泥(000401.SZ)│23.5元人民幣
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.